clinical trial · NCT05046613
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Pfizer·—·recruiting·n = 780
MigraineRimegepantNot taking Rimegepant
brief summary
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
started
Sep 23, 2021
primary completion
Apr 30, 2034
completion
Apr 30, 2034
last updated
Jan 22, 2026
official title
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol